INTRODUCTION
The diverse biological activities of interleukin 1 (IL-I) have attracted interest from a wide range of biological disciplines [1] . After systemic injection into a variety of animals, it seems that IL-I affects nearly every organ system. Interest falls into two groups: (1) those studying the potential beneficial effects of IL-I on host defense mechanisms, particularly the hemopoietic stem cell, and (2) those looking at ways to block the production and/or activity of IL-I, since many of its biological activities are associated with disease processes such as tissue degradation in arthritis and diabetes. Some groups are now preparing to use IL-I in humans to bolster the stem cell's reactivity to colony stimulating factors, while other groups are in clinical trials with new drugs for pain and arthritis which may be effective by reducing production of No doubt the isolation of IL-I receptors is of vital importance to both areas of investigation.
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CLONING OF THE 80 KDA IL-1 BINDING PROTEIN An 80 kDa IL-I specific binding protein has been observed on a variety of cell lines [2] [3] [4] [5] [6] [7] ; it recognizes both IL-la and IL-l:. Treatment of this 80 kDa protein with glycanases reduces its size to about 65 kDa, indicating that the variation in molecular weight sizes reported by several investigators may be due to differential glycosylation. In addition, some experiments using tunicamycin and plant lectins suggest that the glycosylation sites of the 80 kDa IL-I receptor may play a role in receptor affinity [8] .
The 80 kDa IL-I binding protein has been purified to homogeneity from the murine cell line E14 6.1 C10, and the 26 N-terminal amino acids have been determined [9] . Using direct in situ binding a protein has been cloned [10] , and the amino acids derived from the cDNA match the purified protein. [10] , domain 1 is similar to rat CD8 chainII and domain 3 to the CB of the human T-cell receptor; domains 2 and 3 are similar to the murine platelet-derived growth factor receptor. In the extracellular segment, seven distinct glycosylation sites can be observed. The extent of glycosylation appears to be one explanation of the various molecular weights for the IL-I binding proteins.
Since the initial molecular cloning of IL-I: [12] and IL-la [13] , it has been clear that these two proteins are, with the exception of a few stretches, not strictly homologous molecules. The three-dimensional structure of human IL-1lf has been reported [14] , and that study shows completely beta-sheet configuration. Using computerized molecular modeling, IL-la appears also to be a beta-sheet structure [Cohen F: personal communication] . Single point mutations and multiple point amino acid addition to the N-terminal or mutations to the mid-region (histidine) results in marked changes in the affinity of IL-1,8 for receptor binding and biological activity [15, 16] . Similar mutations in the IL-i a molecule have no effect, and it is important to recognize the fact that the majority of receptor binding and cross-linking studies have been reported for IL-i a (since this form survives the labeling process better than IL-I,8). Thus, although the 80 kDa IL-IR recognizes both forms, specific binding between the ligand and its receptor may differ for the two IL-1 forms. Site-directed mutagenesis of the 80 kDa IL-I R will probably clarify this issue.
In human synovial cells, IL-1:f binds with a Kd of 4 pM, whereas IL-Ia has a Kd of 66 pM [17] . Despite this 15- 
TWO CLASSES OF IL-IR
A second class of considerably higher affinity (1-15 pM) IL-1 receptors has been observed by several groups [6] and appears to be distinct from the affinity (>500 pM) of the cloned murine 80 kDa IL-I R. Several possibilities might explain the data on the existence of two classes of IL-IR: (1) [3] ; however, mitogen-stimulated spleen cells apparently show both high-and low-affinity IL-1 receptors [10] . We have also observed on several occasions two classes on EL4 and DI 0.G4. 1 murine T-helper cells [18] .
OTHER IL-1 BINDING PROTEINS
The possibility exists that the IL-I R has other chains, similar to the situation of the IL-2R in that the p55 IL-2R subunit would be comparable to the 80 kDa binding protein (IL-iRf3) and the 30 kDa would represent a putative second chain (IL-IRa) which, like the p70 chain, would be a low-affinity binding protein; however, the present 80 kDa IL-i R (single subunit) has an affinity of about 500 pM, which could indicate that a second chain has an even lower affinity; the two-chain complex would then account for the high (5-15 pM) affinity class of receptor. A second IL-IR has been reported from RAJI cells, a human B-cell lymphoma line, which has a Kd of 2.2 nM for IL-I1 [16, 19] . This putative second IL-IR has a molecular weight of 68 kDa; it appears to be a distinct gene product rather than a breakdown fragment of the 80 kDa IL-IR. Others have isolated monoclonal antibodies to the B-cell surface proteins and one of these monoclonal antibodies immunoprecipitates this 68 kDa IL-i R on B-cells [20] .
In cross-linking experiments, other IL-I specific binding proteins have been observed in addition to the prominent 80 kDa IL-IR. From a structural standpoint, the "two-chain" IL-IR complex has received supporting evidence from Bird et al. [5] , Resch [21] , and from our own studies [18] . The other IL-I binding proteins are 26-30 and 43-45 as well as 110 and 220 kDa. Are there other IL-I binding protein breakdown products or aggregates? These IL-1 binding proteins are specific in that they do not cross-link to radiolabeled IL-I in the presence of competing unlabeled IL-1.
Clearly the small-molecular-weight proteins which are present at approximately 5 to 10 percent of the total IL-I binding the 80 kDa receptor may be breakdown products of the 80 kDa IL-I R; however, time-dependent cross-linking experiments seem to rule out this possibility [21] . Furthermore, proteases are present during the cross-linking and subsequent procedures. In addition, cell membrane preparations also reveal these lower-molecular-weight forms which bind IL-1. As occurred in the case of the appearance of two classes of receptors in mitogen-activated spleen cells [10] , we have been able to increase the binding (cross-linking) of radiolabeled IL-I to the 30 kDa protein by the addition of phytohemagglutinin during the binding process at 40C [18, 22] . Mitogens may cross-link the 30 kDa protein to membrane and allow a more efficient binding to take place. We have also produced antibodies to synthetic peptides of the 80 kDa IL-I R, and these antibodies do not recognize either the 68 or the 30 kDa protein [23] . One possible explanation for the 110 kD binding protein is a complex of the 80 plus the 30 kDa binding proteins, which on SDS-PAGE, would be complexed to IL-I and appear about 125 kD. The 220 kD cross-linked protein may be a dimer of this; however, this possibility remains speculation at the present time. Nevertheless, these smallermolecular-weight IL-I binding proteins are not likely to be artifacts of cross-linking methods since, using Jurkat cells (see below) under the same conditions, we do not observe any significant binding, nor do we observe bands representing the 68 and 30 kDa proteins on SDS-PAGE. This result rules out many cross-linking artifacts.
SIGNAL TRANSDUCTION AND THE IL-IR
Following intravenous injection of IL-I into a variety of animals, responses such as fever, slow-wave sleep, sodium excretion, hypotension, PGE production, and leukopenia occur within five to ten minutes. The vascular endothelium appears to be the likely target for many of these and other biological effects following intravenous IL-1. In vitro, endothelial cells respond to IL-I at 1-10 pM (or less), but IL-I specific binding is difficult to demonstrate or is often absent. Similarly, human neuroblastoma cells will release arachidonic acid within seconds after exposure to fM concentrations of IL-1, but there is no significant binding to these cells [Dransfield D, Bernheim H: personal communication]. Thus the response of these and other cells appears to take place without measurable association of IL-I to a plasma membrane binding receptor. How does IL-I transduce its signal to these cells? One explanation, of course, is that very few receptors need to be occupied for signal transduction to take place. Another explanation is that the affinity of the small-molecular-weight receptors is too low to allow significant cross-linking to take place.
Recent data, however, demonstrate that IL-I may be transducing its signal via a novel mechanism of phospholipid hydrolysis [24] . Using Jurkat cells, IL-I will rapidly increase the liberation of diacylglycerol (DAG), but this increase in DAG takes place in the absence of hydrolysis of phosphatidylinositol 4,5-biphosphate. There is no increase in cytosolic calcium in these cells as others have reported with other cells following exposure to IL-1 [25] . Similarly, there is no increase in inositol triphosphate generation; however, Jurkat cells will release phosphorylcholine from phosphatidylcholine within seconds of exposure to IL-1. The hydrolysis of phosphatidylcholine (PC) at very low concentrations of IL-1 (EC50 = 30 fM) reaches maximal levels at 100 fM. The response is specific; that is, TNF has no effect and either IL-la or IL-1:3 is equally effective. This turnover in PC has also been measured in Dl 0.G4.1, EL4, and human peripheral blood T-cells. Jurkat cells do not express detectable receptors for IL-I (either at 40C or 370C), whereas D10.G4.1 and EL4 cells possess thousands of receptors, and peripheral blood T cells have only marginal numbers of receptors.
These findings suggest that the presence of the 80 kDa binding protein is only indirectly related to signal transduction. Could a putative, second very-low-affinity chain of the IL-I R complex be linked to PC turnover? A similar case may be observed in YT202 cells, which possess only the low affinity p70 IL-2R and when occupied transduce a signal leading to Na+/H+ exchange. In such a model for the IL-i R, the 80 kDa IL-i R would bind IL-I and internalize the molecule or induce a distinct class of signal transduction mechanisms as proposed by Mizel et al. [26] . On the other hand, the low-affinity IL-i Ra chain would not bind with a suffcient affinity for observed binding, but would nevertheless transduce a signal via PC hydrolysis, DAG liberation, and increased protein kinase activation.
The One interesting aspect of this model is that it separates IL-I -induced rapid increases of PGE2 from those that require new gene expression for cyclo-oxygenase [28] . The increase in PGE2 production by a variety of cells in vitro following IL-1 exposure occurs too late to explain the rapid onset of fever, neutropenia, or hypotension following IL-I in vitro. Even the appearance of IL-1-induced phospholipase A2 [29] , a calciumactivated enzyme, occurs too late to explain the release of arachidonic acid from cells incubated with IL-1. This finding is supported by numerous studies showing that IL-I fails to activate intracellular calcium.
One attractive hypothesis to explain the linkage of a putative IL-i R to signal transduction via PC turnover would be to propose that this chain is a glycosylphospholipid anchored cell-surface protein [30] . These interesting cell surface proteins do not have an intracellular segment and are linked to membrane phosphatidylinositol via their carboxyl terminus to ethanolamine and a carbohydrate. Recently a truncated form of the platelet-derived growth factor receptor has been shown to be anchored to the membrane via glycosylphosphatidylinositol linkage [31] . The THY-I alloantigen on murine T-cells is also a glycosylphosphatidylinositol-anchored protein and plays an important role in IL-1 effects on T cell activation [32] . It is possible that there is an IL-I R chain which is a PC-anchored protein.
